$ATYR
aTyr Pharma Inc

2018 Q3 Form 10-Q Financial Statement

#000156459018029559 Filed on November 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q4 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.480M $5.890M $3.690M
YoY Change -32.79% 74.26% 6.34%
% of Gross Profit
Research & Development $4.202M $5.310M $7.133M
YoY Change -41.09% -41.9% -31.38%
% of Gross Profit
Depreciation & Amortization $190.0K $160.0K $150.0K
YoY Change 26.67% -27.27% -31.82%
% of Gross Profit
Operating Expenses $6.677M $11.20M $10.83M
YoY Change -38.33% -10.59% -21.91%
Operating Profit -$6.677M -$10.83M
YoY Change -38.33% -21.91%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$437.0K -$270.0K -$360.0K
YoY Change 21.39% -882.61%
Pretax Income -$7.110M -$11.47M -$11.19M
YoY Change -36.46% -9.11% -19.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.114M -$11.47M -$11.19M
YoY Change -36.43% -8.69% -19.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.338M -$5.385M -$6.082M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.96M $85.12M $90.40M
YoY Change -38.1% 17.98% 28.17%
Cash & Equivalents $31.55M $21.09M $29.77M
Short-Term Investments $24.41M $64.03M $60.60M
Other Short-Term Assets $1.700M $1.900M $1.800M
YoY Change -5.56% -26.92% -41.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $57.65M $86.99M $92.20M
YoY Change -37.48% 16.29% 25.27%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000M $2.280M $2.200M
YoY Change -9.09% 60.45% 37.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $100.0K $90.00K $100.0K
YoY Change 0.0% -72.97% -71.67%
Total Long-Term Assets $2.155M $2.370M $2.300M
YoY Change -6.3% -58.6% -81.34%
TOTAL ASSETS
Total Short-Term Assets $57.65M $86.99M $92.20M
Total Long-Term Assets $2.155M $2.370M $2.300M
Total Assets $59.80M $89.36M $94.50M
YoY Change -36.72% 10.97% 9.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $2.276M $3.600M
YoY Change -83.33% -12.66% 0.98%
Accrued Expenses $2.400M $3.103M $3.900M
YoY Change -38.46% -43.06% -29.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.700M $5.012M $2.300M
YoY Change 234.78% 1378.47% -11.54%
Total Short-Term Liabilities $10.70M $10.39M $9.700M
YoY Change 10.31% 21.89% -18.49%
LONG-TERM LIABILITIES
Long-Term Debt $10.10M $14.72M $12.50M
YoY Change -19.2% 60.02%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.10M $14.72M $12.50M
YoY Change -19.2% 60.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.70M $10.39M $9.700M
Total Long-Term Liabilities $10.10M $14.72M $12.50M
Total Liabilities $20.80M $25.11M $22.20M
YoY Change -6.31% 41.68% 86.55%
SHAREHOLDERS EQUITY
Retained Earnings -$292.4M -$264.2M
YoY Change 22.32%
Common Stock $30.00K $30.00K
YoY Change -99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.99M $64.25M $72.30M
YoY Change
Total Liabilities & Shareholders Equity $59.77M $89.36M $94.50M
YoY Change -36.75% 10.97% 10.01%

Cashflow Statement

Concept 2018 Q3 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$7.114M -$11.47M -$11.19M
YoY Change -36.43% -8.69% -19.02%
Depreciation, Depletion And Amortization $190.0K $160.0K $150.0K
YoY Change 26.67% -27.27% -31.82%
Cash From Operating Activities -$6.460M -$10.30M -$8.900M
YoY Change -27.42% -11.89% -39.41%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$160.0K -$440.0K
YoY Change -90.91% 220.0% 633.33%
Acquisitions
YoY Change
Other Investing Activities $20.76M -$3.370M -$39.32M
YoY Change -152.8% -138.96% -682.52%
Cash From Investing Activities $20.73M -$3.530M -$39.76M
YoY Change -152.14% -141.05% -694.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000M 5.160M 42.50M
YoY Change -104.71% -27.83% -5041.86%
NET CHANGE
Cash From Operating Activities -6.460M -10.30M -8.900M
Cash From Investing Activities 20.73M -3.530M -39.76M
Cash From Financing Activities -2.000M 5.160M 42.50M
Net Change In Cash 12.27M -8.670M -6.160M
YoY Change -299.19% -313.55% -30.47%
FREE CASH FLOW
Cash From Operating Activities -$6.460M -$10.30M -$8.900M
Capital Expenditures -$40.00K -$160.0K -$440.0K
Free Cash Flow -$6.420M -$10.14M -$8.460M
YoY Change -24.11% -12.89% -42.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16836000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24757000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10021000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10827000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31547000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24414000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
64028000
us-gaap Operating Expenses
OperatingExpenses
35945000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26857000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35945000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-788000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
331390000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
328519000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1684000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
57645000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3103000
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
30000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-57000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-120000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292379000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6677000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
10827000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11188000
us-gaap Operating Expenses
OperatingExpenses
26857000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1252089
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5381890
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.52
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.40
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2475000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7133000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3694000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7114000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-11190000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
6677000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11196000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29858393
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7086000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264186000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
38986000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
64245000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59774000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89355000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29865509
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29789162
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29865509
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29789162
us-gaap Net Income Loss
NetIncomeLoss
-28193000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24462835
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
63000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28130000
us-gaap Profit Loss
ProfitLoss
-28193000
us-gaap Profit Loss
ProfitLoss
-36733000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
567000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
552000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2829000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3649000
us-gaap Accretion Expense
AccretionExpense
743000
us-gaap Accretion Expense
AccretionExpense
414000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
213000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-113000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-130000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-182000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-802000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2139000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-725000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26224000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32058000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
585000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1152000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
23375000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
65302000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
63265000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
42347000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39305000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24107000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
28000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
88000
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
4930000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2667000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
42487000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2625000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47542000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10456000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8623000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29765000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38388000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The reclassifications were not material to the condensed consolidated financial statements.</p></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22856669
CY2018Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
11
life Available For Sale Securities In Gross Unrealized Loss Position Maturities Term Maximum
AvailableForSaleSecuritiesInGrossUnrealizedLossPositionMaturitiesTermMaximum
P12M
us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Issuable in three separate tranches (the Term Loans), $10.0 million of which was funded in November 2016, $5.0 million of which was funded in June 2017 and $5.0 million of which was funded in December 2017.
life Noncancelable Operating Leases Term Of Expiration
NoncancelableOperatingLeasesTermOfExpiration
2019-05
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000
CY2017Q2 life Lease Facility
LeaseFacility
24494
CY2018Q3 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
56000000
CY2017Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
175
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
4607
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23758154
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22856669
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23758154
CY2018Q3 life Lease Facility
LeaseFacility
20508
CY2018Q3 life Lease Expiration Term
LeaseExpirationTerm
2023-05
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
240000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
812000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1002000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1031000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1062000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
403000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4550000
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25741183
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4617059
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2029061
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12141
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.92
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.49
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
690000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1189000

Files In Submission

Name View Source Status
0001564590-18-029559-index-headers.html Edgar Link pending
0001564590-18-029559-index.html Edgar Link pending
0001564590-18-029559.txt Edgar Link pending
0001564590-18-029559-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
goclowb2ukgu000001.jpg Edgar Link pending
goclowb2ukgu000002.jpg Edgar Link pending
life-10q_20180930.htm Edgar Link pending
life-20180930.xml Edgar Link completed
life-20180930.xsd Edgar Link pending
life-20180930_cal.xml Edgar Link unprocessable
life-20180930_def.xml Edgar Link unprocessable
life-20180930_lab.xml Edgar Link unprocessable
life-20180930_pre.xml Edgar Link unprocessable
life-ex101_11.htm Edgar Link pending
life-ex311_8.htm Edgar Link pending
life-ex312_6.htm Edgar Link pending
life-ex321_9.htm Edgar Link pending
life-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending